Gilead Sciences (GILD) Q4 2025 (USD): EPS 1.86 (exp. 1.81), Revenue 7.93bln (exp. 7.69bln)
Importance
Level 1
- Raised quarterly dividend by 3.8% to 0.82/shr from 0.79.
Outlook
- FY26 non-GAAP EPS 8.45-8.85 (exp. 8.79).
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#GILEAD SCIENCES INC#GILD.US#FOREX#EQUITIES#METALS#ASIAN SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#GILD#DXY#US EQUITIES